Key facts
- It has raised $28.5M across 1 recorded rounds; the latest was Early Stage VC ($16.0M) in Apr 2023.
- Notable investors include Gaingels, Calm Ventures, Alexandria Venture Investments, Wing Venture Capital, Hawktail — 11 tracked in total.
- OverT Bio has filed 2 Form Ds with the SEC since 2023, most recently May 2024 ($16.0M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for OverT Bio
Funding rounds
1 roundsAbout OverT Bio
Operator of a biotech company intended to provide cell therapy for cancers. The company's cell therapies identify and develop novel genetic modifications that help immune cells overcome barriers created by tumors and lead to effective and durable immunotherapies, enabling the healthcare industry to identify and cure cancer.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2022
- Employees
- 10
- Website
- overt.bio/
- Ownership
- Privately Held (backing)
OverT Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OverT Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OverT Bio in its N-PORT filings yet. We sweep new filings monthly.